Formycon.com

Formycon and Bioeq announce File Acceptance for FYB201, a …

WEBMunich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (“Bioeq”) announce that the U.S. Food and Drug Administration (FDA) …

Actived: 3 days ago

URL: https://www.formycon.com/en/blog/press-release/formycon-and-bioeq-announce-file-acceptance-for-fyb201-a-biosimilar-candidate-to-lucentis-ranibizumab-by-the-u-s-food-and-drug-administration-fda/

Health Canada approves FYB201/Ranopto® (Ranibizumab), a …

WEBMunich, Amsterdam, Zug, Toronto – Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. jointly announce that Health Canada has …

Category: Health Go Health

Formycon announces commercial launch of FYB201 (Ranibizumab) …

WEBMunich, Germany – Formycon AG (FSE: FYB) and Bioeq AG announce the commercial launch of FYB201, a biosimilar to Lucentis ®1 (Ranibizumab), in Canada …

Category: Health Go Health

FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), …

WEBMunich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG (“Bioeq”) announce that the Committee for Medicinal …

Category: Health Go Health

Formycon informs about the current Status of the BLA Review …

WEBMunich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG (“Bioeq”) announce today, that the U.S. Food and Drug …

Category: Food Go Health

Formycon announces successful results of Phase I clinical trial for

WEBMunich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced the successful conclusion of the extended Phase I clinical study comparing …

Category: Health Go Health

Formycon Announces Details of Further Pipeline Product: FYB202 …

WEBMunich – The biosimilars company Formycon has today announced details of a further product from its development pipeline. FYB202 is a biosimilar candidate for Stelara®* …

Category: Health Go Health

Formycon and Fresenius Kabi secure U.S. License Date for …

WEBMunich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and Fresenius Kabi today announced that they have reached a settlement with Johnson & …

Category: Health Go Health

Formycon discloses details on second pipeline product

WEBMunich – Formycon AG today has announced details on the second biosimilar product which is jointly developed with Santo Holding GmbH. FYB203 is a biosimilar candidate …

Category: Health Go Health

Formycon appoints biotech expert Professor Johannes Buchner to …

WEBMunich – The biosimilars company Formycon is underpinning its claim to scientific excellence by appointing Johannes Buchner, professor in Biotechnology at the …

Category: Health Go Health

Formycon AG announces global license agreement with Fresenius …

WEBMunich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to …

Category: Health Go Health

Formycon reports successful first half of 2023

WEBThe Group’s key financial figures developed very positive as of June 30, 2023: Group revenues increased to a total of € 43.8 million in the first half of 2023, more …

Category: Health Go Health

Formycon and Fresenius Kabi conclude global commercialization

WEBMunich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to …

Category: Health Go Health

Senior Scientist as Team Lead Formulation Development (m/f/d)

WEBYour qualifications: Master (or equivalent) and 6-7 years of relevant work experience or PhD and 3 years of relevant work experience or other education and relevant work expertise

Category: Health Go Health